CD8A and neoplasm: Figure 6 depicts our current understanding of how tumour Axl impacts the immune response. Genetic deletion of Axl in the resistant tumour cells leads to an increase in MHCI and myeloid promoting cytokines. Additionally, these key molecular findings correlate with Axl expression in the TCGA breast cancer data set, and our molecular signature correlates with Axl and an EMT gene signature. In this model system, loss of Axl allows the development of antitumour immune response where it was previously suppressed. RT results in greater CD45+, mDC, CD8+ cells, but decreased macrophage infiltration.